Possible Effect of Autologous Blood Stem Cell Transplantation on Outcome of Acute Myeloid Leukemia in First Relapse

  • J. Reiffers
  • G. Marit
  • P. Cony-Makhoul
  • C. Faberes
  • P. Fernandez
  • A. Broustet
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Despite recent progress in the treatment of acute myelogenous leukemia (AML), most patients who achieve complete remission (CR) relapse within 2 years following induction chemotherapy. In some of these latter patients (40%–70%), especially when the duration of first complete remission has been longer than 18 months, a second complete remission may be obtained using different salvage chemotherapeutic regimens. High-dose cytosine arabinoside (HD ARA-C) either alone or in combination with other drugs such as intercalating agents are commonly used in such situations. Once a second CR is achieved, its duration is usually short and does not exceed 1 year in most patients.

Keywords

Toxicity Leukemia Oncol Melphalan Resis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Amadori S, Meloni G, Petti MC, Papa G, Miniero R, Mandelli F (1989) Phase II trial of intermediate dose ARA-C (IDAC) with sequential Mitoxantrone ( MITOX) in acute myelogenous leukemia. Leukemia 3: 112–114PubMedGoogle Scholar
  2. 2.
    Bortin MM, Gale RP, Kay HEM, Rimm AA (1983) For the Advisory Committee of the International Bone Marrow Transplant Registry. Bone marrow transplantation for acute myelogenous leukemia. JAMA 249: 1166–1175PubMedCrossRefGoogle Scholar
  3. 3.
    Gorin NC, Herve P, Aegerter P, Goldstone A, Linch D, Maraninchi D, Burnett A, Helbig W, Meloni G, Verdonck LF, De Witte T, Rizzoli V, Carella A, Parlier Y, Auvert B, Goldman J (1986) For the Working Party on Autologous Bone Marrow Transplantation of the European Bone Marrow Transplantation Group (EBMTG). Autologous bone marrow transplantation for acute leukemia in remission. Br J Haematol 64: 385–395PubMedCrossRefGoogle Scholar
  4. 4.
    Harousseau JL, Reiffers J, Hurteloup P, Milpied N, Guy H, Rigal-Huguet F, Facon T, Dufour P, Ifrah N (1989) For the French Study Group of Idarubicin Leukemia. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cyta-rabine. J Clin Oncol 7: 45–49PubMedGoogle Scholar
  5. 5.
    Heinemann V, Jehn U (1990) Rationales of a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cyto-sine arabinoside. Leukemia 4: 790–796PubMedGoogle Scholar
  6. 6.
    Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Planker M, Donhuijsen-Ant R, Lengfelder E, Arlin Z, Buchner T (1987) High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 14 [Suppl 1]: 73–77PubMedGoogle Scholar
  7. 7.
    Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hustein W (1988) Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia. An active and well-tolerated regimen. J Clin Oncol 6: 213–217PubMedGoogle Scholar
  8. 8.
    Marit G, Cony P, Duclos F, Puntous M, Broustet A, Reiffers J (1990) Treatment of relapsed or refractory acute leukemia: comparison of two different regimens. Haematol Blood Transfus 33: 614–617PubMedGoogle Scholar
  9. 9.
    Reiffers J, Castaigne S, Tilly H, Lepage E, Leverger G, Henon P, Douay L (1987) Hematopoietic reconstitution after autologous blood stem cell transplantation: a report of 46 cases. Plasma Ther Transfus Technol 8: 360–362CrossRefGoogle Scholar
  10. 10.
    Reiffers J, Leverger G, Marit G, Castaigne S, Tilly H, Lepage E, Henon P, Douay L, Troussard X for the France Auto Greffe Group (1989) Haematopoietic reconstitution after autologous blood stem cell transplantation. In: Gale RP, Champlin RE (eds) Bone marrow transplantation: current contro versis. Liss, New York, pp 313–320Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. Reiffers
    • 1
  • G. Marit
    • 1
  • P. Cony-Makhoul
    • 1
  • C. Faberes
    • 1
  • P. Fernandez
    • 1
  • A. Broustet
    • 1
  1. 1.Department of Hematology and Bone Marrow Transplant Unit, CHR BordeauxHôpital Haut- LevêquePessacFrance

Personalised recommendations